📊 QURE Key Takeaways
Is uniQure N.V. (QURE) a Good Investment?
uniQure is a severely unprofitable pharmaceutical company burning $38.2M in operating cash quarterly with only $3.6M in revenue and 14-16 months of cash runway at current burn rate. The catastrophic 40.6% YoY revenue decline, negative operating margin of -1283.5%, and $53.5M net loss indicate failed commercialization of existing products and insufficient pipeline advancement to offset R&D burn.
uniQure N.V. Key Strengths (QURE)
- Strong liquidity with 10.4x current ratio and $140M cash reserves
- Moderate leverage with 0.33x debt-to-equity ratio
- EPS improving year-over-year (-0.85 vs worse prior period) showing loss trajectory narrowing
QURE Stock Risks: uniQure N.V. Investment Risks
- Acute cash runway risk: $38.2M quarterly burn implies 14-16 months until insolvency without capital raise
- Revenue collapsed 40.6% YoY suggesting commercialization failure, discontinued products, or failed partnerships
- Catastrophic profitability metrics: -1283.5% operating margin, -1502.9% net margin, negative ROE of -35.8%
- Negative free cash flow of -$38.4M indicates unsustainable operations requiring immediate strategic intervention
- Early-stage development profile (massive R&D burn) with no indication of near-term revenue inflection
Key Metrics to Watch
- Quarterly revenue trends and sequential burn rate sustainability
- Regulatory approvals, clinical trial milestones, and commercial product launches
- Cash balance depletion rate and capital raise announcements or debt restructuring
uniQure N.V. (QURE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.40x current ratio provides a solid financial cushion.
QURE Profit Margin, ROE & Profitability Analysis
QURE vs Healthcare Sector: How uniQure N.V. Compares
How uniQure N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is uniQure N.V. Stock Overvalued? QURE Valuation Analysis 2026
Based on fundamental analysis, uniQure N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
uniQure N.V. Balance Sheet: QURE Debt, Cash & Liquidity
QURE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: uniQure N.V.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-6.47 indicates the company is currently unprofitable.
QURE Revenue Growth, EPS Growth & YoY Performance
QURE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.6M | -$43.6M | $-0.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
uniQure N.V. Dividends, Buybacks & Capital Allocation
QURE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for uniQure N.V. (CIK: 0001590560)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QURE
What is the AI rating for QURE?
uniQure N.V. (QURE) has an AI grade of D with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QURE's key strengths?
Claude: Strong liquidity with 10.4x current ratio and $140M cash reserves. Moderate leverage with 0.33x debt-to-equity ratio.
What are the risks of investing in QURE?
Claude: Acute cash runway risk: $38.2M quarterly burn implies 14-16 months until insolvency without capital raise. Revenue collapsed 40.6% YoY suggesting commercialization failure, discontinued products, or failed partnerships.
What is QURE's revenue and growth?
uniQure N.V. reported revenue of $3.6M.
Does QURE pay dividends?
uniQure N.V. does not currently pay dividends.
Where can I find QURE SEC filings?
Official SEC filings for uniQure N.V. (CIK: 0001590560) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QURE's EPS?
uniQure N.V. has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is QURE's fundamental grade?
Based on our AI fundamental analysis in June 2026, uniQure N.V. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is QURE stock overvalued or undervalued?
Valuation metrics for QURE: ROE of -35.8% (sector avg: 15%), net margin of -1,502.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is QURE's AI grade for 2026?
Our dual AI analysis gives uniQure N.V. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QURE's free cash flow?
uniQure N.V.'s operating cash flow is $-38.2M, with capital expenditures of $140.0K. FCF margin is -1,077.6%.
How does QURE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,502.9% (avg: 12%), ROE -35.8% (avg: 15%), current ratio 10.40 (avg: 2).